Arrowhead Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia Drug
Dow Jones12-02
By Nicholas G. Miller
The Food and Drug Administration granted breakthrough therapy designation to Arrowhead Pharmaceuticals' plozasiran drug to treat severe hypertriglyceridemia.
The designation expedites the development and review of drugs for which preliminary evidence indicates substantial improvement over available therapies to treat serious conditions.
Arrowhead intends to complete phase three clinical trials of the drug in the middle of next year and submit a supplemental new drug application by the end of 2026.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments